ArticleBreast cancer research : BCR2026
Highly CD81-expressing stromal cells characterize a tumor-suppressive immune microenvironment in invasive breast cancer.
Article in Breast cancer research : BCR, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
1 citing paper in PubMed.
- Cyclin-dependent kinase 4 and 6 inhibitors and the breast cancer immune ecosystem: immune remodeling, resistance, and therapeutic reprogramming.Frontiers in immunology · 2026Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
8 authors.
Funding
Abstract
backgroundCD81, a member of the tetraspanin family, is implicated in tumor progression, and its elevated expression in tumor cells has been associated with poor prognosis across multiple cancers. However, the functional significance of CD81 within the stromal compartments of the tumor microenvironment (TME) remains unclear. This study investigated the clinical relevance and mechanistic role of stromal CD81 (sCD81) in invasive breast cancer.
methodsA total of 462 human primary invasive breast cancer samples, along with 13 normal breast tissues and 10 ductal carcinoma in situ samples collected between 2000 and 2013, were analyzed. Immunohistochemistry and spatial analyses were used to evaluate sCD81 expression, and its association with cancer-associated fibroblast (CAF) subsets and immune components in the TME, as well as correlation with clinicopathological correlations and survival outcome.
resultssCD81 expression was significantly higher in invasive breast cancer than in normal breast stromal tissue but did not differ across clinical subtypes. High sCD81 expression was associated with significantly longer disease-free survival, and multivariate analysis identified sCD81 as an independent prognostic factor alongside nuclear grade, estrogen receptor status, and lymph node metastasis. Co-expression analyses demonstrated that sCD81-high stromal cells exhibited a CD34-positive, FAP-low, and PDGFRα-low phenotype, indicating that they are distinct from established CAF subtypes. Both sCD81 and podoplanin (PDPN) expression correlated with increased immune cell infiltration. However, PDPN-positive CAFs promoted an immunosuppressive TME characterized by enrichment of regulatory T cells and M2-like macrophages, whereas CD81-high stromal cells did not exert such effects. Spatial analyses revealed that CD81-high stromal cells were preferentially localized near tumor vasculature and CCL19-expressing cells, suggesting a potential association with T-cell recruitment into the TME through CCL19-mediated mechanisms.
conclusionsThese findings identify stromal CD81 expression as a novel prognostic marker in invasive breast cancer and highlight its association with a tumor-suppressive immune microenvironment, distinct from the immunosuppressive phenotype typically associated with PDPN-positive CAFs.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.